These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25715810)

  • 1. A nanoparticulate drug-delivery system for glaucocalyxin A: formulation, characterization, increased in vitro, and vivo antitumor activity.
    Han M; Li Z; Guo Y; Zhang J; Wang X
    Drug Deliv; 2016 Sep; 23(7):2457-2463. PubMed ID: 25715810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation, characterization, biodistribution and antitumor efficacy of hydroxycamptothecin nanosuspensions.
    Han M; Liu X; Guo Y; Wang Y; Wang X
    Int J Pharm; 2013 Oct; 455(1-2):85-92. PubMed ID: 23928147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nanoparticulate drug-delivery system for 20(S)-protopanaxadiol: formulation, characterization, increased oral bioavailability and anti-tumor efficacy.
    Han M; Ma L; Yu X; Li Z; Guo Y; Wang X
    Drug Deliv; 2016 Sep; 23(7):2410-2418. PubMed ID: 25564965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, optimization of the inclusion complex of glaucocalyxin A with sulfobutylether-β-cyclodextrin and antitumor study.
    Ren L; Wang J; Chen G
    Drug Deliv; 2019 Dec; 26(1):309-317. PubMed ID: 30896265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Honokiol nanosuspensions: preparation, increased oral bioavailability and dramatically enhanced biodistribution in the cardio-cerebro-vascular system.
    Han M; Yu X; Guo Y; Wang Y; Kuang H; Wang X
    Colloids Surf B Biointerfaces; 2014 Apr; 116():114-20. PubMed ID: 24448177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X; Zhang T; Lan Y; Wu B; Shi Z
    AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characteristic and pharmacological study on inclusion complex of sulfobutylether-β-cyclodextrin with glaucocalyxin A.
    Ren L; Jing J; Chen G; Miao Y; Wei P
    J Pharm Pharmacol; 2014 Jul; 66(7):927-34. PubMed ID: 24697809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of glaucocalyxin A derivatives as potential anticancer agents.
    Yang J; Liu Y; Xue C; Yu W; Zhang J; Qiao C
    Eur J Med Chem; 2014 Oct; 86():235-41. PubMed ID: 25164762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and in vitro-in vivo evaluation of teniposide nanosuspensions.
    He S; Yang H; Zhang R; Li Y; Duan L
    Int J Pharm; 2015 Jan; 478(1):131-137. PubMed ID: 25448575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled release of glaucocalyxin - a self-nanoemulsifying system from osmotic pump tablets with enhanced bioavailability.
    Yanfei M; Guoguang C; Lili R; Pingkai O
    Pharm Dev Technol; 2017 Mar; 22(2):148-155. PubMed ID: 26400477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps.
    Hill A; Geissler S; Meyring M; Hecht S; Weigandt M; Mäder K
    Int J Pharm; 2013 Jul; 451(1-2):57-66. PubMed ID: 23628403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Drug Payload 10-Hydroxycamptothecin Nanosuspensions Stabilized by Cholesterol-PEG: In Vitro and In Vivo Investigation.
    Yang L; Jiang J; Hong J; Di J; Liao Y; Kuang H; Wang X
    J Biomed Nanotechnol; 2015 Apr; 11(4):711-21. PubMed ID: 26310077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
    Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
    Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of hydroxy genkwanin nanosuspensions and their enhanced antitumor efficacy against breast cancer.
    Ao H; Li Y; Li H; Wang Y; Han M; Guo Y; Shi R; Yue F; Wang X
    Drug Deliv; 2020 Dec; 27(1):816-824. PubMed ID: 32489130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect.
    Chen Y; Liu J; Yang X; Zhao X; Xu H
    J Pharm Pharmacol; 2005 Feb; 57(2):259-64. PubMed ID: 15720792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.
    Pu X; Sun J; Wang Y; Wang Y; Liu X; Zhang P; Tang X; Pan W; Han J; He Z
    Int J Pharm; 2009 Sep; 379(1):167-73. PubMed ID: 19505545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide.
    Sahu BP; Das MK
    Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of azithromycin nanosuspensions by reactive precipitation method.
    Hou CD; Wang JX; Le Y; Zou HK; Zhao H
    Drug Dev Ind Pharm; 2012 Jul; 38(7):848-54. PubMed ID: 22092042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preparation, characterization and dissolution characteristics of dragon's blood extract nanosuspensions].
    Wang LF; Chen XN; Li J; Tu PF; Wang JL
    Zhongguo Zhong Yao Za Zhi; 2019 Jun; 44(11):2236-2243. PubMed ID: 31359648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.